Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268874 | 0.98 | KDM4E (0.32) | HRH4KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269267 | 0.94 | CNR1 (0.32) | HRH4KCNH2PIK3CDL3MBTL1KDM4E | |
| SCHEMBL31269189 | 0.92 | HRH4 (0.33) | HRH4KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268841 | 0.92 | CNR1 (0.33) | KCNH2PIK3CDKDM4EALDH1A1LMNA | |
| SCHEMBL31268935 | 0.91 | PDE2A (0.34) | HRH4KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268953 | 0.91 | PDK2 (0.33) | HRH4PIK3CDL3MBTL1LMNA | |
| SCHEMBL31269450 | 0.90 | TLR7 (0.34) | HRH4KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31268950 | 0.90 | KCNH2 (0.32) | HRH4KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL31269061 | 0.90 | MET (0.33) | HRH4KCNH2SCN5ASCN9APIK3CD | |
| SCHEMBL30983456 | 0.90 | PIK3CD (0.35) | HRH4KCNH2SCN5ASCN9APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |